Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Acquisition expands Merck’s growing hematology portfolio
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)